TABLE 2.
Dermal observations at the site of infection with O. tsutsugamushi in infected and vaccinated cynomolgus monkeysa
| Animal ID | Phase I (infection)
|
Phase III (challenge)
|
||||
|---|---|---|---|---|---|---|
| Dose (MuLD50) | Duration, maximum scoreb
|
Dose (MuLD50) | Duration, maximum scoreb
|
|||
| Edema | Erythema | Edema | Erythema | |||
| 1 | 106 | Days 6-15, 3 | Days 6-23, 4 | 106 | 0 | 0 |
| 2 | 104 | Days 8-15, 1 | Days 8-10, 1 | |||
| 3 | 102 | Days 14-15, 1 | Days 14-24, 1 | 106 | 0 | 0 |
| 4 | 101 | 0 | 0 | |||
| 5c | 0 | Day 13, 1 | Day 13, 1 | 106 | Days 5-32, 3 | Days 5-20, 1 |
| 6c | 0 | 0 | 0 | 106 | Days 5-27, 3 | Days 5-20, 1 |
a
No dermal abnormalities were observed during the phase II vaccination period.
b
Scores for edema observations: 0, none (no swelling); 1, minimal (slight swelling); 2, mild (defined swelling [distinct]); 3, moderate (defined swelling [raised]). Scores for erythema observations: 0, none (normal color); 1, minimal (light pink); 2, mild (bright pink/pale red); 3, moderate (bright red); 4, severe (dark red).
c
For phase III, animals 5 and 6 were vaccinated 4 weeks prior to challenge with 850 μg Kp r56.